As we continue to monitor Coronavirus (COVID-19) developments closely, the health and well-being of our team, customers, and their employees is of utmost importance to us.
As a trusted vendor, we understand the imperative of limiting the impact this situation could have on our services. We are keenly focused on maintaining a safe work environment for our team while ensuring continuous service.
We have a robust integrated Business Resiliency Program in place and are committed to keeping our operations running smoothly.
This Plan includes:
Minimizing supply chain disruptions through constant communications with our production facilities and logistics partners
Maintaining larger stock levels of products at our distribution facility
Prioritizing orders being shipped based on the order in which they were received
Enabling work from home capabilities for our sales and support staff
Providing our team members with information and best practices to prevent the spread of any illness
Coordinating communications with our team, associates, customers and partners
Limiting all non-essential business travel
In the short term, you might experience a slightly longer than anticipated lead time for fulfilment of some the orders. Please be assured, we are taking every measure to ensure minimal disruptions or delays and continue to monitor this fluid situation on a daily basis.
Thank you for your business, and your continued support.
Dimitry Fedorov, President
Scientific Wavefront News & Blog
Partial recovery of visual function in a blind patient after optogenetic therapy
A recent study by researchers at the University of Pittsburgh and the University of Basel has had success in restoration of some vision in a patient suffering from retinitis pigmentosa using optogenetic stimulation with specially engineered goggles.
Retinitis pigmentosa is a rare, progressive, inherited eye disease resulting in degeneration of photoreceptor cells in the retina which can ultimately lead to complete blindness. With this loss of photosensitive cells, the researchers aimed to have retinal ganglion cells respond to light. One eye of the patient was injected with ChrimsonR into the central retina of the most-impaired eye. ChrimsonR is a light-sensing protein delivered via an adeno-associated viral vector, with a peak stimulation of 590 nm. Light stimulation was provided via a set of goggles that had a special camera that took images from the patients surroundings, detecting changes in light intensity and projecting corresponding light pulses onto the retina in real time.
This therapy took place 4 months after therapy injection, with results in visual improvement after seven months of training. Tests showed that the patient could perceive, locate, count, and touch objects when his eye was stimulated with the goggles. The patient also saw improvements in day-to-day activities such as navigating around daily household furniture and objects.
The vision regained is limited, not allowing enough resolution for face identification, or reading. Further trials are also needed to fully understand the safety and efficacy of this approach. However, the results from this trial provide a promising future for optogenetics stimulation and vision restoration. Even if current sigh restoration is not optimal, this is a landmark to help bring further researchers into the field.Â
Full access to the materials and methodology can be found byÂ clicking here.
Details on the yellow lasers laser like the ones used in the research can be found here:
Click here to learn more about the 589 nm laser used in the research.
Click hereÂ to learn more about the 593 nm laser used in the research.